Abstract

Population-level mortality from NSCLC in the United States fell sharply from 2013 to 2016, and survival after diagnosis improved substantially. Our analysis suggests that a reduction in incidence along with treatment advances - particularly approvals for and use of targeted therapies - is likely to explain the reduction in mortality observed during this period.

Keywords

MedicineLung cancerIncidence (geometry)PopulationEpidemiologyCancerRelative survivalInternal medicineOncologyMortality rateDemographyCancer registryEnvironmental health

MeSH Terms

CarcinomaNon-Small-Cell LungFemaleHumansIncidenceLung NeoplasmsMaleMortalitySEER ProgramSex FactorsUnited States

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
383
Issue
7
Pages
640-649
Citations
1606
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1606
OpenAlex
47
Influential
1344
CrossRef

Cite This

Nadia Howlader, Gonçalo Forjaz, Meghan J. Mooradian et al. (2020). The Effect of Advances in Lung-Cancer Treatment on Population Mortality. New England Journal of Medicine , 383 (7) , 640-649. https://doi.org/10.1056/nejmoa1916623

Identifiers

DOI
10.1056/nejmoa1916623
PMID
32786189
PMCID
PMC8577315

Data Quality

Data completeness: 90%